Description

  • Product name

  • Purity

    70 - 90% by HPLC.

  • Accession

  • Animal free

    No
  • Nature

    Synthetic
    • Species

      Rat
    • Predicted molecular weight

      125 kDa
    • Modifications

      phospho T980

Specifications

Our Abpromise guarantee covers the use of ab195521 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Form

    Liquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

    Information available upon request.

General Info

  • Alternative names

    • DKFZp781H1925
    • E2AK3_HUMAN
    • EC 2.7.11.1
    • Eif2ak3
    • Eukaryotic translation initiation factor 2 alpha kinase 3
    • Eukaryotic translation initiation factor 2-alpha kinase 3
    • Heme regulated EIF2 alpha kinase
    • HRI
    • HsPEK
    • Pancreatic eIF2 alpha kinase
    • Pancreatic eIF2-alpha kinase
    • PEK
    • PRKR like endoplasmic reticulum kinase
    • PRKR-like endoplasmic reticulum kinase
    • WRS
    see all
  • Function

    Phosphorylates the alpha subunit of eukaryotic translation-initiation factor 2 (EIF2), leading to its inactivation and thus to a rapid reduction of translational initiation and repression of global protein synthesis. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin D1.
  • Tissue specificity

    Ubiquitous. A high level expression is seen in secretory tissues.
  • Involvement in disease

    Defects in EIF2AK3 are the cause of Wolcott-Rallison syndrome (WRS) [MIM:226980]; also known as multiple epiphyseal dysplasia with early-onset diabetes mellitus. WRS is a rare autosomal recessive disorder, characterized by permanent neonatal or early infancy insulin-dependent diabetes and, at a later age, epiphyseal dysplasia, osteoporosis, growth retardation and other multisystem manifestations, such as hepatic and renal dysfunctions, mental retardation and cardiovascular abnormalities.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. GCN2 subfamily.
    Contains 1 protein kinase domain.
  • Domain

    The lumenal domain senses perturbations in protein folding in the ER, probably through reversible interaction with HSPA5/BIP.
  • Post-translational
    modifications

    Autophosphorylated.
    N-glycosylated.
  • Cellular localization

    Endoplasmic reticulum membrane.
  • Information by UniProt

References

ab195521 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab195521.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up